Market Overview

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement

Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug candidate which induces double-stranded DNA breaks to cause cell death.

Posted-In: News Contracts FDA

 

Most Popular

Related Articles (MYGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free